Abstract |
This study meta-analysed randomized, double-blind, placebo controlled trials in patients with intermittent claudication of the lower limbs comparing ticlopidine to placebo in order to test the hypothesis that the drug, a pure antiplatelet agent, is able to reduce the incidence of thrombotic cardio-vascular events on atherosclerotic arteries in these patients. A highly significant reduction, from 9% to 3% (p ranging from 0.006 to 0.002), was observed for fatal or non-fatal cardio-vascular events in a total of 611 patients (301 with ticlopidine, 310 with placebo). The duration of follow-up ranged from 6 to 12 months. Side-effects, defined as withdrawal from study medication for any reason but death, cardio-vascular events or cancer, were 2.4 times more frequent in the ticlopidine treated patients as compared to placebo. We concluded that in this high risk population, prevention of cardio-vascular events is likely to be effective.
|
Authors | J P Boissel, J C Peyrieux, J M Destors |
Journal | Thrombosis and haemostasis
(Thromb Haemost)
Vol. 62
Issue 2
Pg. 681-5
(Sep 29 1989)
ISSN: 0340-6245 [Print] Germany |
PMID | 2683189
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Cardiovascular Diseases
(mortality, prevention & control)
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Intermittent Claudication
(complications)
- Leg
- Male
- Meta-Analysis as Topic
- Randomized Controlled Trials as Topic
- Risk Factors
- Ticlopidine
(adverse effects, therapeutic use)
|